View AMCP comments to the FDA on considerations in demonstrating biosimilar interchangeability with a biologic reference product.
AMCP Letter on Adult CE and Stabilize Medicaid and CHIP Coverage Act
On Aug. 13, AMCP joined dozens of national and state advocacy organizations in a sign-on letter calling on House and Senate leadership to strengthen patients’ access to high-quality health coverage and care. Specifically, the letter urges Congress to support 12-month continuous eligibility for adults in Medicaid and the Children’s Health Insurance Program (CHIP) by passing the Stabilize Medicaid and CHIP Coverage Act (H>R. 5434/S. 3138).
Related
View AMCP comments in response to the 21st Century Cures 2.0 Request for Information.
On June 13, AMCP joined 24 patient and provider organizations in applauding the Supreme Court's unanimous ruling reversing the Fifth Circuit's decision in Alliance for Hippocratic Medicine et al. v FDA et al. AMCP and the undersigned organizations unequivocally support FDA's role in safeguarding patients, which has yielded approval of tens of thousands of crucial medications and devices for generations of Americans.
Featured News & Resources
See Full Calendar
Webinars
A New Era in RSV Prevention
Other Events
Mid-South AMCP Biosimilar Implementation
Other Events
Mid-South AMCP Federal and State Legislative Update
News & Resources by Topic
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
